Earnings Call Insights: Coloplast A/S (OTCPK:CLPBF) Q1 2025 CEO Kristian Villumsen highlighted 8% organic growth and a reported EBIT margin of 27% for Q1 2025, which aligned with expectations.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The global Urinary Incontinence Devices Market, valued at US$3.82 billion in 2023, is forecasted to grow at a robust CAGR of 11.2%, ...

Coloplast (CSE: COLOb) has been upgraded to an "outperform" rating by RBC Capital Markets, with analysts citing a positive risk-reward balance and a price target increase to DKK 940 per share from DKK ...

On Monday, RBC Capital Markets analyst Jack Reynolds-Clark revised the rating for Coloplast (CSE:COLOb) A/S (COLOB:DC) (OTC: CLPBY), elevating it from Sector Perform to Outperform. Accompanying this ...

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...